Tetra Bio-Pharma filed patent applications for its therapeutic, ARDS-003
by CM staff
These three patent applications become part of Tetra's IP portfolio, which includes, 14 granted patents.
MONTREAL — Tetra Bio-Pharma Inc. is filing three patent applications for its therapeutic, ARDS-003. The three patents include:
- International patent under PCT (Patent Cooperation Treaty) related to the methodology, including improvements, for the synthesis of target synthetic cannabinoid derivatives, specifically HU308 (known as Onternabez) and HU433. (Methods, Processes, and Compositions for Improved Preparation of HU308 and HU433 Application No. PCT/CA2021/051327)
- International PCT application related to the pharmaceutical methods of production and uses of the compositions comprising Onternabez, suitable for parenteral delivery. (Parenteral Cannabinoid Formulations and Uses Thereof Application No. PCT/CA2021/051882).
- Provisional patent application with the United States Patent and Trademark Office related to crystalline Onternabez and uses thereof. This application covers identification of novel polymorphs and cocrystals of Onternabez, which will allow for extended patent protection on Onternabez and may lead to improvements in stability and solubility when formulating Onternabez for future drug products.
“This is a significant step in protecting our novel therapeutic, ARDS-003,” said Guy Chamberland, CEO and chief regulatory officer, Tetra. “It is especially significant, considering the potential use of this novel cannabinoid molecule in antiviral and immunomodulator therapies. These patents would be enforceable once granted and provide additional protection to investors for up to 20 years from the filing date.”
These three patent applications become part of Tetra’s IP portfolio, which includes, 14 granted/issued patents, as well as one provisional and five PCT applications pending across international and national jurisdictions.
